In the news
In the news
Press Releases
01-20-2025
Leaps by Bayer Publishes Breakthrough Study in Collaboration with BCG
Read01-13-2025
BlueRock Therapeutics advances investigational cell therapy bemdaneprocel for treating Parkinson’s disease to registrational Phase III clinical trial
Read10-24-2024
Bayer and Dewpoint Therapeutics sign Licensing Agreement for Heart Disease Program
Read05-28-2024
Bayer advances genome-editing initiatives for nutrition enhanced vegetables
Read02-13-2024
Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M
Read
Press coverage of Leaps and portfolio companies
- Fast Company
March 18, 2025
These 10 biotech companies are changing how we discover new drugs and treat complex diseases
- The New York Times
- Fast Company
March 05, 2025
This Gates-backed startup can fine-tune plants for specific purposes—without ever touching their genes
- The New York Times
February 03, 2025
F.D.A. Approves Studies of Pig Organ Transplants for Kidney Patients
- Fast Company
November 19, 2024
The 4 next big technologies in food and agriculture for 2024
- Endpoints News
Leaps events
Spotlight on Juergen Eckhardt
Juergen Eckhardt is EVP and Head of Leaps by Bayer, the impact investment arm, and Head of Business Development, & Licensing (BD&L) for the Pharmaceuticals division. He is a medical doctor and venture investor in healthcare, biotech, and agriculture with more than 20 years of experience. He is a strong believer that scientific breakthroughs can help us overcome some of humanity’s biggest challenges, including to cure and prevent chronic disease and to feed an ever-growing world population in a sustainable way – in short: science for a better life. He holds an MD from the University of Basel, Switzerland, and an MBA from INSEAD in Fontainebleau, France.
Read More
Op-eds by Juergen Eckhardt
Reports
Explore the latest reports and publications developed by Leaps by Bayer and our collaborators.
Find out how people in the US feel about breakthrough science in our Breakthrough Study Snapshot Report, a collaboration with BCG and market research by IPSOS.
Download
Find out how people around the world feel about breakthrough science in our Breakthrough Study, a collaboration with BCG and market research by IPSOS.
Download
Read about our 2024 milestones, portfolio company highlights, engagement activities, and more.
Download
Learn about our custom impact measurement framework WALY and read about the impact magnitude of our portfolio.
Download
Learn how to bring AgTech products from concept to market.
Download
Read about our 2023 milestones, portfolio company highlights, engagement activities, and more.
Download
See how our 10 Leaps framework could generate return for humanity.
Download
Read about our 2022 milestones, portfolio company highlights, engagement activities, and more.
Download
Press Kit
Leaps by Bayer is the impact investment arm of Bayer AG. We invest in teams pursuing fundamental breakthroughs in life science, targeting 10 huge challenges facing humanity.
Some call them impossible. We call them “Leaps”.
Media Contact
Kira Peikoff
Kira Peikoff is a former journalist who covered emerging biotechnologies for publications including The New York Times, Newsweek, and Popular Mechanics. She now leads communications for Leaps by Bayer.
Our return to humanity
The Leaps team brings together a diverse group of individuals with expertise in biotech, healthcare, agriculture, investment, and communication.